Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metaclipse SARS-CoV-2 vaccine
- Development stage
- Preclinical
- Lead developer
- Metaclipse Therapeutics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Metaclipse Therapeutics is developing a preclinical SARS-CoV-2 vaccine candidate using its proprietary VaxRex™ platform. The VaxRex™ technology utilizes virus-like particles (VLPs) or non-living bacterial membrane vesicles to present viral antigens alongside membrane-anchored biological adjuvants. This design is intended to elicit potent humoral and cellular immunity, specifically targeting high-risk populations such as the elderly and immunocompromised individuals. The platform was originally licensed from Emory University and aims to enhance immune responses by combining viral antigens with specialized biological adjuvants. In June 2020, the company was awarded a $2.2 million SBIR Phase II contract from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the candidate toward clinical trials.
- Other names
- Metaclipse COVID-19 vaccineVaxRex COVID-19 vaccineVaxRex SARS-CoV-2 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Metaclipse SARS-CoV-2 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Metaclipse SARS-CoV-2 vaccine.